Shire to Buy Baxalta for $32 Billion

Shire announced today that it has entered into an agreement to acquire Baxalta under a cash and stock deal valued at $45.57 per share, or approximately $32 billion.

The combination of Baxalta and Shire would reportedly create "the number-one rare diseases platform in revenue and pipeline depth", with best-in-class products in each of the following franchises: hematology, immunology, neuroscience, lysosomal storage diseases, gastrointestinal/endocrine, and hereditary angioedema (HAE).

Shire CEO Flemming Ornskov said that the expanded portfolio "will drive our growth to over $20 billion in anticipated annual revenues by 2020."